Unlike every other Big Pharma company in the world, Novartis ($NVS) tends to prefer to communicate rather selectively when it chops a facility here or winnows out its ranks over there in its global structure. Specifics on the secretive Basel-based company tend to leak out through local reports, if at all, with releases targeted at … Continue reading
Novartis has confimred that pharma jobs will be reallocated in 2014 in a continuation of the productivity drive that saved the firm $2.8bn (EUR2bn) last year. Swiss newspaper NZZ am Sonntag reported that Novartis was looking to cut or transfer up to 4,000 jobs – approximately 6% of its global workforce – earlier this week. … Continue reading
Swiss drugmaker Novartis plans to reorganise parts of its domestic workforce, cutting up to 500 jobs in its pharmaceutical division to free resources for new roles to support the product launches, the company said on Tuesday. The redeployment comes as new chairman Joerg Reinhardt casts a fresh eye over the company’s operations as part of … Continue reading
Novartis AG will close its Ciba Vision plant in Mississauga, Ont., next year, laying off 300 workers, another in a growing list of factory shutdowns in the province. The plant, which has been making contact-lens solution for about three decades, will start winding down in May with the full closing slated for the end of … Continue reading
Novartis AG (NOVN) plans to close two sites in Europe, move staff from California to the Boston area and cut about 500 jobs in an effort consolidate its research operations, especially in respiratory diseases. Novartis plans to close sites in Horsham, England, and Vienna and move cancer research from Emeryville, California, to Cambridge, Massachusetts, Eric … Continue reading
Swiss pharmaceuticals giant Novartis has arranged a crisis meeting of scientists, NHS trustees and Government officials starting today in London in a bid to streamline Britain’s “haphazard” approach to medical research and development (R&D). Science Minister David Willetts is due to attend the meeting, thought to be the first to unite representatives of Big Pharma … Continue reading
After years of flying high, biopharma job growth is running into turbulence, a number of factors have increasingly pushed big pharma into layoffs. Although the picture is bleak now, the industry’s longer-term employment prospects appear brighter. Roche will eliminate 1,000 jobs by the end of 2013 when it shuts down its Nutley, NJ, R&D site. … Continue reading